author-photo

Adriane M Zernhelt

Merck & Co.

4

Papers

1242

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (1097)
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

2014 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (144)
1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

2011 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)